Cutaneous Mycobacterium kansasii infection involves M. kansasii affecting the skin. When the isolate is rifampin-susceptible, current guidelines specify a structured multidrug antimycobacterial approach with defined treatment goals.
Management centres on a multidrug antimycobacterial regimen, with the recommended treatment course extending beyond 12 months.
DOI: 10.3389/fphar.2023.1242156
According to the official ATS/ERS/ESCMID/IDSA clinical practice guidelines, for patients with rifampin-susceptible M. kansasii, a treatment course lasting over 12 months, comprising rifampicin, ethambutol, and either isoniazid or a macrolide, is advised.
These assessments typically involve evaluating the complete or substantial disappearance of preexisting skin lesions, the absence of new skin lesions, and the persistence of unchanged skin lesions after a specific duration of treatment.
Treatment outcome includes bacteriological negative conversion, bacteriological cure, clinical cure, cure, treatment failure, bacteriological recurrence, and death.
View source ↗